The impact of COVID-19 pandemic can be felt across the Healthcare Industry The growing inability in the production and manufacturing processes, in the light of the self-quarantined workforce has caused a major disruption in the supply chain across the sector. Restrictions encouraged by this pandemic are obstructing the production of essentials such as life-saving drugs.

The nature of operation in Pharmaceuticals plants that cannot be easily stopped and started, makes the operational restrictions in these plants a serious concern for the industry leaders. Restricted and delayed shipments from China have created a price hike in the raw materials, affecting the core of the Healthcare Industry.

Central nervous system comprises brain and spinal cord, and is responsible for integration of sensory information. Brain is the largest and one of the most complex organs in the human body. It is made up of 100 billion nerves that communicate with 100 trillion synapses. It is responsible for the thought and movement produced by the body. Spinal cord is connected to a section of brain known as brain stem and runs through the spinal canal. The brain processes and interprets sensory information sent from the spinal cord. Brain and spinal cord serve as the primary processing centers for the entire nervous system, and control the working of the body.

For detailed insights on enhancing your product footprint, request for a sample here @ https://www.persistencemarketresearch.com/samples/4160

Neuroprosthetics improves or replaces the function of the central nervous system. Neuroprosthetics, also known as neural prosthetics, are devices implanted in the body that stimulate the function of an organ or organ system that has failed due to disease or injury. It is a brain-computer interface device used to detect and translate neural activity into command sequences for prostheses. Its primary aim is to restore functionality in patients suffering from loss of motor control such as spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, and stroke. The major types of neuroprosthetics include sensory implants, motor prosthetics, and cognitive prosthetics. Motor prosthetics support the autonomous system and assist in the regulation or stimulation of affected motor functions.

Similarly, cognitive prosthetics restore the function of brain tissue loss in conditions such as paralysis, Parkinsons disease, traumatic brain injury, and speech deficit. Sensory implants pass information into the bodys sensory areas such as sight or hearing, and it is further classified as auditory (cochlear implant), visual, and spinal cord stimulator. Some key functions of neuroprosthetics include providing hearing, seeing, feeling abilities, pain relief, and restoring damaged brain cells. Cochlear implant is among the most popular neuroprosthetics. In addition, auditory brain stem implant is also a neuroprosthetic meant to improve hearing damage.

North America dominates the global market for neuroprosthetics due to the rising incidence of neurological diseases and growth in geriatric population in the region. Asia is expected to display a high growth rate in the next five years in the global neuroprosthetics market, with China and India being the fastest growing markets in the Asia-Pacific region. Among the key driving forces for the neuroprosthetics market in developing countries are the large pool of patients, increasing awareness about the disease, improving healthcare infrastructure, and rising government funding in the region.

For entire list of market players, request for TOC here @ https://www.persistencemarketresearch.com/toc/4160

Increasing prevalence of neurological diseases such as traumatic brain injury, stroke and Parkinsons disease, rise in geriatric population, increase in healthcare expenditure, growing awareness about healthcare, rapid progression of technology, and increasing number of initiatives by various governments and government associations are some key factors driving growth of the global neuroprosthetics market. However, factors such as high cost of devices, reimbursement issues, and adverse effects pose a major restraint to the growth of the global neuroprosthetics market.

Innovative self-charging neural implants that eliminate the need for high risk and costly surgery to replace the discharge battery and controlling machinery with thoughts would help to develop opportunities for the growth of the global neuroprosthetics market.

Pre-Book Right Now for Exclusive Analyst Support @ https://www.persistencemarketresearch.com/checkout/4160

The major companies operating in the global neuroprosthetics market are ,

Key geographies evaluated in this report are:

Key features of this report

Continue reading here:
Revenue from the Sales of Neuroprosthetics Market to Surge Exponentially Owing To High Demand During COVID-19 Lockdown and Forecast 2015 to 2021 -...

Spinal Cord Stem Cells Comments Off on Revenue from the Sales of Neuroprosthetics Market to Surge Exponentially Owing To High Demand During COVID-19 Lockdown and Forecast 2015 to 2021 -… | May 26th, 2020

Key points:

NEW YORK, May 25, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that clinical outcomes of its allogeneic mesenchymal stem cell (MSC) medicine RYONCIL (remestemcel-L) in children and adults with steroid-refractory acute graft versus host disease (GVHD) have been published in three peer-reviewed articles and an accompanying editorial in the May issue of Biology of Blood and Marrow Transplantation, the official publication of the American Society for Transplantation and Cellular Therapy.

Mesoblast Chief Medical Officer Dr Fred Grossman said: Results from these three trials show a consistent pattern of safety and efficacy for RYONCIL (remestemcel-L) in patients with the greatest levels of inflammation and the most severe grades of acute GVHD. These clinical outcomes provide a compelling rationale for use of remestemcel-L in children and adults with other conditions associated with severe inflammation and cytokine release, including acute respiratory distress syndrome (ARDS) and systemic vascular manifestations of COVID-19 infection.

In the accompanying editorial, Dr Jacques Galipeau, Professor and Assistant Dean of Medicine at the Stem Cell & Regenerative Medicine Center at the University of WisconsinMadison and Chair of the International Society of Cell and Gene Therapy (ISCT) MSC Committee, concluded that after more than a decade of clinical study involving three distinct advanced trials, it appears that remestemcel-L might well have finally met the regulatory requirements for marketing approval in the United States for steroid refractory acute GVHD in children, and it is to be determined whether this industrial MSC product will find utility for adults afflicted by acute GVHD or other indications.

The trials highlighted in the three articles all evaluated the same treatment regimen of RYONCIL, with patients receiving twice weekly intravenous infusions of 2 million cells per kg body weight over a four-week period. RYONCIL was well-tolerated in all studies with no identified safety concerns. The three trials were:

1. Study 275: An Expanded Access Program in 241 children across 50 centers in eight countries where RYONCIL was used as salvage therapy for steroid-refractory acute GVHD in patients who failed to respond to steroid therapy as well as multiple other agents.

2. Study GVHD001/002: A Phase 3 single-arm trial in 55 children across 20 centers in the United States where RYONCIL was used as the first line of treatment for children who failed to respond to steroids for acute GVHD.

3. Study 280: A Phase 3 randomized placebo-controlled trial in 260 patients, including 28 children, across 72 centers in seven countries where RYONCIL or placebo were added to second line therapy in patients with steroid-refractory acute GVHD who failed to respond to steroid treatment.

About Acute Graft Versus Host Disease Acute GVHD occurs in approximately 50% of patients who receive an allogeneic bone marrow transplant (BMT). Over 30,000 patients worldwide undergo an allogeneic BMT annually, primarily during treatment for blood cancers, and these numbers are increasing.1 In patients with the most severe form of acute GVHD (Grade C/D or III/IV) mortality is as high as 90% despite optimal institutional standard of care.2,3 There are currently no FDA-approved treatments in the United States for children under 12 with steroid-refractory acute GVHD.

About RYONCILTM Mesoblasts lead product candidate, RYONCIL (remestemcel-L), is an investigational therapy comprising culture-expanded mesenchymal stem cells derived from the bone marrow of an unrelated donor. It is administered to patients in a series of intravenous infusions. RYONCIL is believed to have immunomodulatory properties to counteract the inflammatory processes that are implicated in SR-aGVHD by down-regulating the production of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues.

References 1. Niederwieser D, Baldomero H, Szer J. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant 2016; 51(6):778-85.2. Westin, J., Saliba, RM., Lima, M. (2011) Steroid-refractory acute GVHD: predictors and outcomes. Advances in Hematology 2011;2011:601953.3. Axt L, Naumann A, Toennies J (2019) Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation 2019;54(11):1805-1814.

About MesoblastMesoblast Limited (Nasdaq:MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. The Companys proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblasts Biologics License Application to seek approval of its product candidate RYONCIL (remestemcel-L) for pediatric steroid-refractory acute graft versus host disease (acute GVHD) has been accepted for priority review by the United States Food and Drug Administration (FDA), and if approved, product launch in the United States is expected in 2020. Remestemcel-L is also being developed for other inflammatory diseases in children and adults including moderate to severe acute respiratory distress syndrome. Mesoblast is completing Phase 3 trials for its product candidates for advanced heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblasts licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.

Mesoblast has a strong and extensive global intellectual property (IP) portfolio with protection extending through to at least 2040 in all major markets. This IP position is expected to provide the Company with substantial commercial advantages as it develops its product candidates for these conditions.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see http://www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

Forward-Looking StatementsThis announcement includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of Mesoblast and its collaborators clinical studies; Mesoblast and its collaborators ability to advance product candidates into, enroll and successfully complete, clinical studies; the timing or likelihood of regulatory filings and approvals; and the pricing and reimbursement of Mesoblasts product candidates, if approved; the potential benefits of strategic collaboration agreements and Mesoblasts ability to maintain established strategic collaborations; Mesoblasts ability to establish and maintain intellectual property on its product candidates and Mesoblasts ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblasts actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For further information, please contact:

Go here to read the rest:
Clinical Outcomes Using RYONCIL (remestemcel-L) in Children and Adults With Severe Inflammatory Graft Versus Host Disease Published in Three Articles...

Bone Marrow Stem Cells Comments Off on Clinical Outcomes Using RYONCIL (remestemcel-L) in Children and Adults With Severe Inflammatory Graft Versus Host Disease Published in Three Articles… | May 25th, 2020

Market Expertz has very recently published a report on the Stem Cell Banking market, which delves deeper into a bunch of insightful as well as comprehensive information about the Stem Cell Banking industrys ecosystem. The research report on the Stem Cell Banking market covers both qualitative as well as quantitative details that focus entirely on the various parameters such as Stem Cell Banking market risk factors, challenges, industrial developments, new opportunities available in the Stem Cell Banking report. These factors are the ones that determine the functioning and trends in the forecasted period for the market.

This is the most recent report inclusive of the COVID-19 effects on the functioning of the market. It is well known that some changes, for the worse, were administered by the pandemic on all industries. The current scenario of the business sector and pandemics impact on the past and future of the industry are covered in this report.

Avail your copy of the sample of the report on the global Stem Cell Banking [emailprotected] https://www.marketexpertz.com/sample-enquiry-form/122606

With the growing number of new players entering the Stem Cell Banking market, expansion in businesses is also improving. Then Stem Cell Banking report focuses on boosting a series of parameters such as revenue shares, optimizing cost structure, offering better services, Stem Cell Banking market demand or supply chain, development policies, which mainly maps to streamline business processes during the projected timeline.

The fundamental drivers, as well as restraints, are identified by the recent trends and historical milestones gathered by the Stem Cell Banking market. It also demonstrates the brief evaluation of the investments, Stem Cell Banking production, innovative technologies, and growth rate of the specific businesses.

Leading Stem Cell Banking manufacturers/companies operating at both regional and global levels:

Cord Blood Registry (CBR) Systems (US), Cordlife Group Limited (Singapore), Cryo-Cell International (US), ViaCord (US), Cryo-Save AG (Netherlands), LifeCell International (India), StemCyte (US), Global Cord Blood Corporation (China), Smart Cells International (UK), Vita34 AG (Germany), and CryoHoldco (Mexico).

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Order Your Copy Now (Customized report delivered as per your specific requirement) @ https://www.marketexpertz.com/checkout-form/122606

The creative advancements are investigated widely to understand the probable impact on the growth of the global Stem Cell Banking market.

The Stem Cell Banking market has been segmented into key segments such as product types, end-users, leading regions, and noteworthy players. The readers can assess detailed and strategical information about each segment. The Stem Cell Banking market report also includes a blend of statistics about sales, consumption rate, volume, value, gross margin, and more.

The segmentation included in the report is beneficial for readers to capitalize on the selection of appropriate segments for the Stem Cell Banking sector and can help companies in deciphering the optimum business move to reach their desired business goals.

product landscape:

Placental Stem Cells (PSCS), Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells , (HESCS), Dental Pulp-Derived Stem Cells (DPSCS)

Application landscape:

Sample Preservation and Storage, Sample Analysis, Sample Processing, Sample Collection and Transportation

End user landscape:

Personalized Banking Applications, Research, Clinical Application

The report includes accurately drawn facts and figures, along with graphical representations of vital market data. The research report sheds light on the emerging market segments and significant factors influencing the growth of the industry to help investors capitalize on the existing growth opportunities.

To get in-depth insights into the global Stem Cell Banking market, reach out to us @ https://www.marketexpertz.com/customization-form/122606

Thus, with the rising adoption of the Stem Cell Banking market in the international sector, the industry for the global Stem Cell Banking market is expected to represent a predicted outlook during the forecast phase from 2020-2027. Additionally, the report on the Stem Cell Banking market delivers a systematic representation of the growth opportunities, Stem Cell Banking market dynamics, and the existing trends are anticipated to shape the growth of the Stem Cell Banking market across the globe.

Geographically, this report studies the top producers and consumers in these key regions:

North America

Europe

China

Japan

Southeast Asia

India

A conscious effort is made by the subject matter experts to analyze how some business owners succeed in maintaining a competitive edge while the others fail to do so makes the research interesting. A quick review of the realistic competitors makes the overall study a lot more interesting. Opportunities that are helping product owners size up their business further add value to the overall study.

!!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted [emailprotected] https://www.marketexpertz.com/discount-enquiry-form/122606

The Stem Cell Banking Market Research/Analysis Report addresses the following questions:

Read the full Research Report along with a table of contents, facts and figures, charts, graphs, etc. @ https://www.marketexpertz.com/industry-overview/2020-stem-cell-banking-global-market

To summarize, the global Stem Cell Banking market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:Planning to invest in market intelligence products or offerings on the web? Then marketexpertz has just the thing for you reports from over 500 prominent publishers and updates on our collection daily to empower companies and individuals catch-up with the vital insights on industries operating across different geography, trends, share, size and growth rate. Theres more to what we offer to our customers. With marketexpertz you have the choice to tap into the specialized services without any additional charges.

Contact Us:John WatsonHead of Business Development40 Wall St. 28th floor New York CityNY 10005 United StatesDirect Line: +1-800-819-3052Visit our News Site: http://newssucceed.com

Follow this link:
Impact of Covid-19 on Stem Cell Banking Market 2020: Remarking Enormous Growth with Recent Trends | Cord Blood Registry (CBR) Systems (US), Cordlife...

Bone Marrow Stem Cells Comments Off on Impact of Covid-19 on Stem Cell Banking Market 2020: Remarking Enormous Growth with Recent Trends | Cord Blood Registry (CBR) Systems (US), Cordlife… | May 25th, 2020

Text Size:A- A+

The killer is not the virus but the immune response.

The current pandemic is unique not just because it is caused by a new virus that puts everyone at risk, but also because the range of innate immune responses is diverse and unpredictable. In some it is strong enough to kill. In others it is relatively mild.

My research relates to innate immunity. Innate immunity is a persons inborn defense against pathogens that instruct the bodys adaptive immune system to produce antibodies against viruses. Those antibody responses can be later used for developing vaccination approaches. Working in the lab of Nobel laureate Bruce Beutler, I co-authored the paper that explained how the cells that make up the bodys innate immune system recognize pathogens, and how overreacting to them in general could be detrimental to the host. This is especially true in the COVID-19 patients who are overreacting to the virus.

Also read: All the Covid-19 symptoms you didnt know about

I study inflammatory response and cell death, which are two principal components of the innate response. White blood cells called macrophages use a set of sensors to recognize the pathogen and produce proteins called cytokines, which trigger inflammation and recruit other cells of the innate immune system for help. In addition, macrophages instruct the adaptive immune system to learn about the pathogen and ultimately produce antibodies.

To survive within the host, successful pathogens silence the inflammatory response. They do this by blocking the ability of macrophages to release cytokines and alert the rest of the immune system. To counteract the viruss silencing, infected cells commit suicide, or cell death. Although detrimental at the cellular level, cell death is beneficial at the level of the organism because it stops proliferation of the pathogen.

For example, the pathogen that caused the bubonic plague, which killed half of the human population in Europe between 1347 and 1351, was able to disable, or silence, peoples white blood cells and proliferate in them, ultimately causing the death of the individual. However, in rodents the infection played out differently. Just the infected macrophages of rodents died, thus limiting proliferation of the pathogen in the rodents bodies which enabled them to survive.

The silent response to plague is strikingly different from the violent response to SARS-CoV-2, the virus that causes COVID-19. This suggests that keeping the right balance of innate response is crucial for the survival of COVID-19 patients.

Also read: If I had Covid-19 am I immune? This is what scientists know so far

Heres how an overreaction from the immune system can endanger a person fighting off an infection.

Some of the proteins that trigger inflammation, named chemokines, alert other immune cells like neutrophils, which are professional microbe eaters to convene at the site of infections where they can arrive first and digest the pathogen.

Others cytokines such as interleukin 1b, interleukin 6 and tumor necrosis factor guide neutrophils from the blood vessels to the infected tissue. These cytokines can increase heartbeat, elevate body temperature, trigger blood clots that trap the pathogen and stimulate the neurons in the brain to modulate body temperature, fever, weight loss and other physiological responses that have evolved to kill the virus.

When the production of these same cytokines is uncontrolled, immunologists describe the situation as a cytokine storm. During a cytokine storm, the blood vessels widen further (vasolidation), leading to low blood pressure and widespread blood vessel injury. The storm triggers a flood of white blood cells to enter the lungs, which in turn summon more immune cells that target and kill virus-infected cells. The result of this battle is a stew of fluid and dead cells, and subsequent organ failure.

The cytokine storm is a centerpiece of the COVID-19 pathology with devastating consequences for the host.

When the cells fail to terminate the inflammatory response, production of the cytokines make macrophages hyperactive. The hyperactivated macrophages destroy the stem cells in the bone marrow, which leads to anemia. Heightened interleukin 1b results in fever and organ failure. The excessive tumor necrosis factor causes massive death of the cells lining the blood vessels, which become clotted. At some point, the storm becomes unstoppable and irreversible.

One strategy behind the treatments for COVID is, in part, based in part on breaking the vicious cycle of the cytokine storm. This can be done by using antibodies to block the primary mediators of the storm, like IL6, or its receptor, which is present on all cells of the body.

Inhibition of tumor necrosis factor can be achieved with FDA-approved antibody drugs like Remicade or Humira or with a soluble receptor such as Enbrel (originally developed by Bruce Beutler) which binds to tumor necrosis factor and prevents it from triggering inflammation. The global market for tumor necrosis factor inhibitors is US$22 billion.

Drugs that block various cytokines are now in clinical trials to test whether they are effective for stopping the deadly spiral in COVID-19.

Alexander (Sasha) Poltorak, Professor of Immunology, Tufts University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Also read: Covid vaccine research in India at nascent stage, breakthrough unlikely this year: Experts

ThePrint is now on Telegram. For the best reports & opinion on politics, governance and more, subscribe to ThePrint on Telegram.

Subscribe to our YouTube channel.

Link:
Coronavirus isnt the killer, our immune response is - ThePrint

Bone Marrow Stem Cells Comments Off on Coronavirus isnt the killer, our immune response is – ThePrint | May 25th, 2020

New York City, United States The change during the COVID-19 pandemic has overhauled our dependence on pattern setting developments, for instance, expanded reality, computer generated reality, and the Healthcare web of things. The unfulfilled cash related targets are persuading the relationship to grasp robotization and forefront advancements to stay ahead in the market competition. Associations are utilizing this open entryway by recognizing step by step operational needs and showing robotization in it to make an automated structure as far as might be feasible

Medical skin care products are used for beautifying or to address some other skin care problems. The cosmetic industry is booming and skin care forms a very huge part of this industry. The aesthetic appearance is so important that people spend a lot on skin care products and treatment. People being more technologically aware of the various new skin care products trending in the market. In addition to the aesthetic application, the medical skin care products are also used to address issues such as acne, pimples or scars.

Request to Sample report @https://www.persistencemarketresearch.com/samples/18469

Medical Skin Care Products Market: Drivers and Restraints

The medical skin care products is primarily driven by the need of natural based active ingredients products which are now trending in the market. Consumers demand medical skin care products which favor health and environment. Moreover, the consumers are updated with the trends so that various companies end up providing such products to satisfy the customers. For instance, a single product face mask has thousands of different variants. This offers consumers different options to select the product depending on the skin type. Moreover, the market players catering to the medical skin care products are offering products with advanced technologies. For instance, Santinov launched the CICABEL mask using stem cell material based on advanced technologies. The stem cells used in the skin care product helps to to protect and activate the cells and promote the proliferation of skin epidermal cells and the anagenesis of skin fibrosis.

Medical Skin Care Products Market: Segmentation

On the basis of product type the medical skin care products market can be segmented as:

On the basis of application, the medical skin care products market can be segment as:

On the basis of distribution channel, the medical skin care products market can be segment as:

Request For TOC @ https://www.persistencemarketresearch.com/toc/18469

Medical Skin Care Products Market: Overview

Medical skin care products are used to address basic skin problems ranging from acne to scars. There are various advancements in the ingredients used to offer skin care products to the consumers. For instance, the use of hyaluronic acid and retinoids is the latest development in the industry. The anti-aging creams are at the forefront as the help treating issues such as wrinkles, scars, acne, and sun damage. Another, product in demand is the probiotic skincare which include lactobacillus and bifidobacterium.

Medical Skin Care Products Market: Region-wise Outlook

In terms of geography, medical skin care products market has been divided into five regions including North- America, Asia- Pacific, Middle-East & Africa, Latin America and Europe. North America dominated the global medical skin care products market as international players are acquiring domestic companies to make their hold strong in the U.S. LOral is accelerating its U.S. market by signing a definitive agreement with Valeant Pharmaceuticals International Inc. to acquire CeraVe, AcneFree and Ambi skin-care brands for US$ 1.3 billion. The acquisition is expected LOreal to get hold of the brands in the price-accessible segment. Asia Pacific is expected to be the fastest growing region owing to the increasing disposable income and rising awareness towards the skin care products.

For in-depth competitive analysis, buy[emailprotected]https://www.persistencemarketresearch.com/checkout/18469

Medical Skin Care Products Market: Key Market Participants

Some of the medical skin care products market participants are ,

Report Highlights:

Originally posted here:
Advancements in Medical Skin Care Products Market to boost Revenues Through COVID-19 Crisis Phase and Forecast 2017 2025 - WaterCloud News

Skin Stem Cells Comments Off on Advancements in Medical Skin Care Products Market to boost Revenues Through COVID-19 Crisis Phase and Forecast 2017 2025 – WaterCloud News | May 25th, 2020

Heart problems associated with spinal muscular atrophy(SMA) may be caused partially by calcium dysregulation in heart muscle cells in the absence of the survival motor neuron(SMN) protein, a study suggests.

These findings shed light not only on the underlying mechanisms of heart problems in SMA which may open new therapeutic avenues but also support the monitoring of heart function in this patient population.

The study, SMN-deficiency disrupts SERCA2 expression and intracellular Ca2+ signaling in cardiomyocytes from SMA mice and patient-derived iPSCs, was published in the journal Skeletal Muscle.

SMA is caused by the loss of SMN, a protein produced in several cell types throughout the body and involved inmultiple and fundamental cellular processes. While SMN deficiency in motor nerve cells is considered the diseases root cause, increasing evidence suggests that other cells and organs in the body also are particularly affected, including the heart.

Cardiovascular problems have been reported in patients with the most severe severeforms of SMA and in mouse models of the disease. Moreover, a previous study supported by theSMA Foundation showed that SMA patients have higher-than-normal levels of several heart failure markers, suggesting that sufficient levels of SMN are essential for normal heart function.

However, the mechanisms behind these SMA-associated heart problems remain largely unknown and no study has established that SMN deficiency directly affects heart function.

Researchers have now evaluated whether SMN deficiency compromised the contractile function of heart cells isolated from a mouse model of a severe form of SMA and also those generated from SMA patients-derived induced pluripotent stem cells (iPSCs).

iPSCs are fully matured cells that researchers can reprogram in a lab dish to revert them back to a stem cell state that has the capacity to differentiate into almost any type of cell.

Results showed that the levels of three heart failure markers atrial natriuretic peptide, brain natriuretic peptide, and skeletal alpa-actin were significantly increased in heart tissue from SMA mice prior to considerable neuromuscular degeneration, compared with that from healthy mice.

This suggested that mechanical function of the heart may be altered early in the disease progression of this severe SMA mouse model, the researchers wrote.

In agreement, heart cells from SMA mice showed impaired contractile function, compared with cells from healthy mice. The team noted that contraction problems in the heart often are associated with calcium dysregulation and lower levels of SERCA2, an enzyme that controls calcium levels inside cells.

Further analysis showed that SMN-deficient heart cells, from both SMA mice and SMA patients, had a significant drop in SERCA2 levels and impaired calcium dynamics, compared with healthy cells.

Notably, these deficits were at least partially corrected when patient-derived cells were modified to increase their production of SMN protein. Conversely, heart cells derived from healthy individuals and forced to lower their SMN production mimicked the deficits seen in SMN-deficient heart cells.

These results demonstrate that SMN regulates SERCA2 [levels] and intracellular [calcium dynamics] in [heart cells] that may impair cardiac function and lead to elevation of heart failure markers, as observed in mice and patients with SMA, the researchers wrote.

The data also suggest that heart cell dysfunction occurs early in the disease course and therefore is likely to be a direct result of SMN loss and not secondary to neurodegeneration, the team noted.

Since deficits in calcium dynamics also were previously reported to occur in SMN-deficient motor nerve cells, the researchers hypothesized that calcium dysregulation may be a common disease mechanism in SMA.

Finally, while neuromuscular degeneration remains the hallmark feature of the disease, impaired heart function may be a contributing factor in disease progression that will require monitoring in light of new therapies that are improving motor function and extending survival, the researchers wrote.

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

Total Posts: 85

Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.

Link:
Study: Heart Problems in SMA May Be Tied to Calcium Dysregulation - SMA News Today

Cardiac Stem Cells Comments Off on Study: Heart Problems in SMA May Be Tied to Calcium Dysregulation – SMA News Today | May 25th, 2020

Global Stem Cell Reconstructive Marketwas valued US$ XX Mn in 2019 and is expected to reach US$ XX Mn by 2027, at a CAGR of 24.5% during a forecast period.

Market Dynamics

The Research Report gives an in-depth account of the drivers and restraints in the stem cell reconstructive market. Stem cell reconstructive surgery includes the treatment of injured or dented part of body. Stem cells are undifferentiated biological cells, which divide to produce more stem cells. Growing reconstructive surgeries led by the rising number of limbs elimination and implants and accidents are boosting the growth in the stem cell reconstructive market. Additionally, rising number of aged population, number of patients suffering from chronic diseases, and unceasing development in the technology, these are factors which promoting the growth of the stem cell reconstructive market. Stem cell reconstructive is a procedure containing the use of a patients own adipose tissue to rise the fat volume in the area of reconstruction and therefore helping 3Dimentional reconstruction in patients who have experienced a trauma or in a post-surgical event such as a mastectomy or lumpectomy, brain surgery, or reconstructive surgery as a result of an accident or injury. Stem cell reconstructive surgeries are also used in plastic or cosmetic surgeries as well. Stem cell and regenerative therapies gives many opportunities for development in the practice of medicine and the possibility of an array of novel treatment options for patients experiencing a variety of symptoms and conditions. Stem cell therapy, also recognised as regenerative medicine, promotes the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/54666/

The common guarantee of all the undifferentiated embryonic stem cells (ESCs), foetal, amniotic, UCB, and adult stem cell types is their indefinite self-renewal capacity and high multilineage differentiation potential that confer them a primitive and dynamic role throughout the developmental process and the lifespan in adult mammal.However, the high expenditure of stem cell reconstructive surgeries and strict regulatory approvals are restraining the market growth.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Global Stem Cell Reconstructive Market Segment analysis

Based on Cell Type, the embryonic stem cells segment is expected to grow at a CAGR of XX% during the forecast period. Embryonic stem cells (ESCs), derived from the blastocyst stage of early mammalian embryos, are distinguished by their capability to distinguish into any embryonic cell type and by their ability to self-renew. Owing to their plasticity and potentially limitless capacity for self-renewal, embryonic stem cell therapies have been suggested for regenerative medicine and tissue replacement after injury or disease. Additionally, their potential in regenerative medicine, embryonic stem cells provide a possible another source of tissue/organs which serves as a possible solution to the donor shortage dilemma. Researchers have differentiated ESCs into dopamine-producing cells with the hope that these neurons could be used in the treatment of Parkinsons disease. Upsurge occurrence of cardiac and malignant diseases is promoting the segment growth. Rapid developments in this vertical contain protocols for directed differentiation, defined culture systems, demonstration of applications in drug screening, establishment of several disease models, and evaluation of therapeutic potential in treating incurable diseases.

Global Stem Cell Reconstructive Market Regional analysis

The North American region has dominated the market with US$ XX Mn. America accounts for the largest and fastest-growing market of stem cell reconstructive because of the huge patient population and well-built healthcare sector. Americas stem cell reconstructive market is segmented into two major regions such as North America and South America. More than 80% of the market is shared by North America due to the presence of the US and Canada.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/54666/

Europe accounts for the second-largest market which is followed by the Asia Pacific. Germany and UK account for the major share in the European market due to government support for research and development, well-developed technology and high healthcare expenditure have fuelled the growth of the market. This growing occurrence of cancer and diabetes in America is the main boosting factor for the growth of this market.

The objective of the report is to present a comprehensive analysis of the Global Stem Cell Reconstructive Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding Global Stem Cell Reconstructive Market dynamics, structure by analysing the market segments and projects the Global Stem Cell Reconstructive Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Stem Cell Reconstructive Market make the report investors guide.Scope of the Global Stem Cell Reconstructive Market

Global Stem Cell Reconstructive Market, By Sources

Allogeneic Autologouso Bone Marrowo Adipose Tissueo Blood Syngeneic OtherGlobal Stem Cell Reconstructive Market, By Cell Type

Embryonic Stem Cell Adult Stem CellGlobal Stem Cell Reconstructive Market, By Application

Cancer Diabetes Traumatic Skin Defect Severe Burn OtherGlobal Stem Cell Reconstructive Market, By End-User

Hospitals Research Institute OthersGlobal Stem Cell Reconstructive Market, By Regions

North America Europe Asia-Pacific South America Middle East and Africa (MEA)Key Players operating the Global Stem Cell Reconstructive Market

Osiris Therapeutics NuVasives Cytori Therapeutics Takeda (TiGenix) Cynata Celyad Medi-post Anterogen Molmed Baxter Eleveflow Mesoblast Ltd. Micronit Microfluidics TAKARA BIO INC. Tigenix Capricor Therapeutics Astellas Pharma US, Inc. Pfizer Inc. STEMCELL Technologies Inc.

MAJOR TOC OF THE REPORT

Chapter One: Stem Cell Reconstructive Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Stem Cell Reconstructive Market Competition, by Players

Chapter Four: Global Stem Cell Reconstructive Market Size by Regions

Chapter Five: North America Stem Cell Reconstructive Revenue by Countries

Chapter Six: Europe Stem Cell Reconstructive Revenue by Countries

Chapter Seven: Asia-Pacific Stem Cell Reconstructive Revenue by Countries

Chapter Eight: South America Stem Cell Reconstructive Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Stem Cell Reconstructive by Countries

Chapter Ten: Global Stem Cell Reconstructive Market Segment by Type

Chapter Eleven: Global Stem Cell Reconstructive Market Segment by Application

Chapter Twelve: Global Stem Cell Reconstructive Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Stem Cell Reconstructive Market Report at:https://www.maximizemarketresearch.com/market-report/global-stem-cell-reconstructive-market/54666/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

Read more:
Global Stem Cell Reconstructive Market- Industry Analysis and Forecast... - Azizsalon News

Cardiac Stem Cells Comments Off on Global Stem Cell Reconstructive Market- Industry Analysis and Forecast… – Azizsalon News | May 25th, 2020

The health focus today is squarely on the bodys natural defense system. Until there is a vaccination, preventative measures are all we can turn to. Ayurveda can help, experts believe, especially a technique thats been gaining popularity. It's called Photo Bio Modulation (PBM). Availableat Indus Valley AyurvedicCentre (IVAC) in Mysore, itsan emerging medical practicein which exposure to low-level laser light or light-emitting diodes stimulates cellular function. This results in beneficial clinical outcomes for various conditions and diseases, primarily low immunity, in addition to lung disorders, respiratory disorders, joint problems, skin issues, and stress.

How does it work?Also known as Low-Level Laser Therapy (LLLT), it increases the production of Adenosine Triphosphate (ATP) in the mitochondria of the cells, which scavenges the free radicals. By doing so, it stimulates stem cell proliferation, lymph nodes associated with respiratory tract, the immune system and stimulates local tissues to support lung function leading to protection from asthma, bronchitis, pneumonia and Chronic Obstructive Pulmonary Disease, says Dr Talavane Krishna, Founder,President, IVAC.

Nasal ApplicationWhile PBM is gaining prominence now, processes such as nasal application, part of Panchakarma (five actions) treatment, have been a standard Ayurvedic antidote to viruses for aeons. One has to apply different herbal powders, liquid extracts, medicated ghee or oil inside the nostrils. Medications like Anu Taila, sesame or coconut oil, Brahmi ghrutha etc are antimicrobial and act as a protective filter inside the nose and throatthe primary entry point for the viruses. This simple procedure could be a daily practice for both adults and children.

Oil pulling Likewise, oil pulling with sesame or coconut oil as a daily oral health practice is useful. It involves swishing a teaspoon of oil in the mouth for three-five minutes and then spitting the oil, followed by washing/brushing the mouth. This kills bacteria that may lead to tooth decay, bad breath, and gum disease.

Rasayana This is one of the eight major branches of Ayurveda. Popularly known as a form of rejuvenation therapy, not only does it focus on anti-aging, but also immunity. This is accomplished by taking certain Ayurvedic preparations, food based on body constitution, and following an Ayurvedic way of life. This increases Ojas, the very essence of the bodys immunity. Medicines include single herbs like Ashwagandha, Shatavari, Amrita, and formulations like Chyavanaprash, Triphala, Makaradhwaja, notto mention regular body-mind detoxifications like Panchakarma and Rejuvenation.

Balance is keyKeeping the body alignedwith its natural rhythms is a prerequisite to the success of your health. For this, Ayurvedic principles namely Dhincharya (daily regime) and Rithucharya (seasonal regime) are crucial. Dhinacharya looks at aspects such as oral hygiene, yoga, pranayama, meditation, diet, bowel movements and more. Ritucharya describes the various changes in our body during the different seasonsand its effect on health. Italso teaches us how to keepa good balance.

The importance of dietcannot be negated, therefore ensure you add ginger, garlic, pepper, turmeric, clove, cumin, fenugreek and cinnamon in your food as all these ingredients build the immunesystem and bring aboutperfect balance, says Gita Ramesh, Joint MD, Kairali Ayurvedic Group.Dont forget to take warm showers and apply sesame oil on the entire body before the morning bath. Allow nostrils to be lubricated by application of cow ghee or oil, and do warm turmeric water gargles regularly, says Dr Aruna Bhide, Senior Ayurveda Doctor and Consultant, Mercure Goa Devaaya Retreat. Breathing exerciseslike Anulom vilom pranayama (alternate breathing), Kapal bhati (forceful exhalation) and Nadi shuddhi pranayama are beneficial too. Keep in mind to exercise until you sweat as this is the best way to excrete toxins.

Potions for healing(Do consult an Ayurvedic doctor)

Indukantha Kashyam Prevents the recurrence of debilitating diseases and keeps the body healthyVilwadi GulikaA tablet used as a treatment for insect bites, rodent bites, gastroenteritis etc.

Chyawanprash High in Vitamin C, it aids in the production of haemoglobinand white blood cells

Kushmandarasayana Comes in a herbal jam form and is used in respiratory conditions

TriphalaGhritam Support bowel health and aids digestion. As an antioxidant, its also thought to detoxify the body and support immunity.

AshwagandhaIt has demonstrated excellent immune-boosting effects, and has also shown to encourage anti-inflammatory and disease-fighting immune cells, thatkeep illnesses at bay

Amrita Used as a blood purifierMakaradhwaja A mineral-based preparation used for its aphrodisiac characteristics, it enhances the effectiveness of several medicines

Read the rest here:
COVID-19: The Prevention Prescription - The New Indian Express

Skin Stem Cells Comments Off on COVID-19: The Prevention Prescription – The New Indian Express | May 24th, 2020

Bone marrow aspirationand trephine biopsy are usually performed on the back of the hipbone, or posterior iliac crest. An aspirate can also be obtained from the sternum (breastbone). For the sternal aspirate, the patient lies on their back, with a pillow under the shoulder to raise the chest. A trephine biopsy should never be performed on the sternum, due to the risk of injury to blood vessels, lungs or the heart.

The need to selectively isolate and concentrate selective cells, such as mononuclear cells, allogeneic cancer cells, T cells and others, is driving the market. Over 30,000 bone marrow transplants occur every year. The explosive growth of stem cells therapies represents the largest growth opportunity for bone marrow processing systems.

Get More Information at Professional:https://www.trendsmarketresearch.com/report/sample/3374

Europe and North America spearheaded the market as of 2018, by contributing over 74.0% to the overall revenue. Majority of stem cell transplants areconducted in Europe, and it is oneof the major factors contributing to the lucrative share in the cell harvesting system market.

In 2018, North America dominated the research landscape as more than 54.0% of stem cell clinical trials were conducted in this region. The region also accounts for the second largest number of stem cell transplantation, which is further driving the demand for harvesting in the region.

Asia Pacific is anticipated to witness lucrative growth over the forecast period, owing to rising incidence of chronic diseases and increasing demand for stem cell transplantation along with stem cell-based therapy.

Japan and China are the biggest markets for harvesting systems in Asia Pacific. Emerging countries such as Mexico, South Korea, and South Africa are also expected to report lucrative growth over the forecast period. Growing investment by government bodies on stem cell-based research and increase in aging population can be attributed to the increasing demand for these therapies in these countries.

Major players operating in the global bone marrow processing systems market are ThermoGenesis (Cesca Therapeutics inc.), RegenMed Systems Inc., MK Alliance Inc., Fresenius Kabi AG, Harvest Technologies (Terumo BCT), Arthrex, Inc. and others.

More Info of Impact Covid19 @ https://www.trendsmarketresearch.com/report/covid-19-analysis/3374

Link:
Bone Marrow Processing Systems Market Quantitative Market Analysis, Current and Future Trends the COVID-19 - Cole of Duty

Bone Marrow Stem Cells Comments Off on Bone Marrow Processing Systems Market Quantitative Market Analysis, Current and Future Trends the COVID-19 – Cole of Duty | May 24th, 2020

Bone marrow aspiration and trephine biopsy are usually performed on the back of the hipbone, or posterior iliac crest. An aspirate can also be obtained from the sternum (breastbone). For the sternal aspirate, the patient lies on their back, with a pillow under the shoulder to raise the chest. A trephine biopsy should never be performed on the sternum, due to the risk of injury to blood vessels, lungs or the heart.

Get Access to sample pages @ https://www.trendsmarketresearch.com/report/sample/3184

The need to selectively isolate and concentrate selective cells, such as mononuclear cells, allogeneic cancer cells, T cells and others, is driving the market. Over 30,000 bone marrow transplants occur every year. The explosive growth of stem cells therapies represents the largest growth opportunity for bone marrow processing systems.Europe and North America spearheaded the market as of 2016, by contributing over 74.0% to the overall revenue. Majority of stem cell transplants are conducted in Europe, and it is one of the major factors contributing to the lucrative share in the cell harvesting system market.

In 2016, North America dominated the research landscape as more than 54.0% of stem cell clinical trials were conducted in this region. The region also accounts for the second largest number of stem cell transplantation, which is further driving the demand for harvesting in the region.Asia Pacific is anticipated to witness lucrative growth over the forecast period, owing to rising incidence of chronic diseases and increasing demand for stem cell transplantation along with stem cell-based therapy.

Japan and China are the biggest markets for harvesting systems in Asia Pacific. Emerging countries such as Mexico, South Korea, and South Africa are also expected to report lucrative growth over the forecast period. Growing investment by government bodies on stem cell-based research and increase in aging population can be attributed to the increasing demand for these therapies in these countries.

Major players operating in the global bone marrow processing systems market are ThermoGenesis (Cesca Therapeutics inc.), RegenMed Systems Inc., MK Alliance Inc., Fresenius Kabi AG, Harvest Technologies (Terumo BCT), Arthrex, Inc. and others

Covid 19 Impact [emailprotected] https://www.trendsmarketresearch.com/report/covid-19-analysis/3184

See the original post:
Bone Marrow Processing System Market: Development Factors and Investment Analysis by Leading Manufacturers - Cole of Duty

Bone Marrow Stem Cells Comments Off on Bone Marrow Processing System Market: Development Factors and Investment Analysis by Leading Manufacturers – Cole of Duty | May 24th, 2020

The killer is not the virus but the immune response.

The current pandemic is unique not just because it is caused by a new virus that puts everyone at risk, but also because the range of innate immune responses is diverse and unpredictable. In some it is strong enough to kill. In others, it is relatively mild.

My research relates to innate immunity. Innate immunity is a persons inborn defense against pathogens that instruct the bodys adaptive immune system to produce antibodies against viruses. Those antibody responses can be later used for developing vaccination approaches. Working in the lab of Nobel laureate Bruce Beutler, I co-authored the paper that explained how the cells that make up the bodys innate immune system recognise pathogens, and how overreacting to them in general could be detrimental to the host. This is especially true in the Covid-19 patients who are overreacting to the virus.

I study inflammatory response and cell death, which are two principal components of the innate response. White blood cells called macrophages use a set of sensors to recognise the pathogen and produce proteins called cytokines, which trigger inflammation and recruit other cells of the innate immune system for help. In addition, macrophages instruct the adaptive immune system to learn about the pathogen and ultimately produce antibodies.

To survive within the host, successful pathogens silence the inflammatory response. They do this by blocking the ability of macrophages to release cytokines and alert the rest of the immune system. To counteract the viruss silencing, infected cells commit suicide, or cell death. Although detrimental at the cellular level, cell death is beneficial at the level of the organism because it stops proliferation of the pathogen.

For example, the pathogen that caused the bubonic plague, which killed half of the human population in Europe between 1347 and 1351, was able to disable, or silence, peoples white blood cells and proliferate in them, ultimately causing the death of the individual. However, in rodents the infection played out differently. Just the infected macrophages of rodents died, thus limiting proliferation of the pathogen in the rodents bodies which enabled them to survive.

The silent response to plague is strikingly different from the violent response to SARS-CoV-2, the virus that causes Covid-19. This suggests that keeping the right balance of innate response is crucial for the survival of Covid-19 patients.

Heres how an overreaction from the immune system can endanger a person fighting off an infection. Some of the proteins that trigger inflammation, named chemokines, alert other immune cells like neutrophils, which are professional microbe eaters to convene at the site of infections where they can arrive first and digest the pathogen.

Others cytokines such as interleukin 1b, interleukin 6 and tumor necrosis factor guide neutrophils from the blood vessels to the infected tissue. These cytokines can increase heartbeat, elevate body temperature, trigger blood clots that trap the pathogen and stimulate the neurons in the brain to modulate body temperature, fever, weight loss and other physiological responses that have evolved to kill the virus.

When the production of these same cytokines is uncontrolled, immunologists describe the situation as a cytokine storm. During a cytokine storm, the blood vessels widen further a process known an vasolidation leading to low blood pressure and widespread blood vessel injury. The storm triggers a flood of white blood cells to enter the lungs, which in turn summon more immune cells that target and kill virus-infected cells. The result of this battle is a stew of fluid and dead cells, and subsequent organ failure.

The cytokine storm is a centerpiece of the Covid-19 pathology with devastating consequences for the host.

When the cells fail to terminate the inflammatory response, production of the cytokines make macrophages hyperactive. The hyperactivated macrophages destroy the stem cells in the bone marrow, which leads to anemia. Heightened interleukin 1b results in fever and organ failure. The excessive tumor necrosis factor causes massive death of the cells lining the blood vessels, which become clotted. At some point, the storm becomes unstoppable and irreversible.

One strategy behind the treatments for Covid-19 is, in part, based on breaking the vicious cycle of the cytokine storm. This can be done by using antibodies to block the primary mediators of the storm, like IL6, or its receptor, which is present on all cells of the body.

Inhibition of tumor necrosis factor can be achieved with FDA-approved antibody drugs like Remicade or Humira or with a soluble receptor such as Enbrel originally developed by Bruce Beutler which binds to tumor necrosis factor and prevents it from triggering inflammation. The global market for tumor necrosis factor inhibitors is $22 billion.

Drugs that block various cytokines are now in clinical trials to test whether they are effective for stopping the deadly spiral in Covid-19.

Alexander (Sasha) Poltorak, Professor of Immunology, Tufts University.

This article first appeared on The Conversation.

Read the rest here:
What is a cytokine storm? And why is its prevention key to treating Covid-19? - Scroll.in

Bone Marrow Stem Cells Comments Off on What is a cytokine storm? And why is its prevention key to treating Covid-19? – Scroll.in | May 24th, 2020

Exosome Therapeutic Marketanalyses the current market size, status, enterprise competition pattern, advantages and disadvantages of enterprise products, development trends regional industrial layout characteristics and macroeconomic policies and industrial policy. By focusing on all the necessities and requirements of the businesses for achieving a successful business growth, the Exosome Therapeutic Market Report are created. The CAGR values estimate the fluctuation about the rise or fall of demand for the specific forecasted period with respect to investment. The Exosome Therapeutic Market report also recognizes and analyses the expanding trends along with major drivers, restraints, challenges and opportunities in the market.

Exosome Therapeutic Marketis expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018.

Get Sample Report: To Know the Impact of COVID-19 on this[emailprotected]https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market

Synopsis of Global Exosome Therapeutic Market:-Exosomes is used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Some Of The Major Competitors Currently Working In Global Exosome Therapeutic Market Are:Bayer AG, Iso-Tex Diagnostics, Inc., Bracco Diagnostic Inc., Novalek Pharmaceuticals Pvt. Ltd., iMAX, Taejoon Pharm, Unijules Medicals Ltd, General Electric, Guerbet LLC, J.B.Chemicals & Pharmaceuticals Ltd among others players domestic and global. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

For More Information or Query or Customization Before Buying, Visit @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market

North America Dominates The Exosome Therapeutic Market as the U.S. Is leaderin exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

Browse in-depth TOC on Exosome Therapeutic Market

50 Tables

250 No of Figures

150 Pages

This Exosome Therapeutic Market report contains all aspects that are directly or indirectly related to the multiple areas of the global market. Our experts have carefully collated the global Exosome Therapeutic Market data and estimated the change in the forecast period. This information in the report helps customers make accurate decisions about market activity Exosome Therapeutic Market based on forecasting trends. This report also discusses current or future policy research or regulations that must be initiated by management and market strategies.

Buy This Report (Single User Access)@https://www.databridgemarketresearch.com/checkout/buy/singleuser/gl

Global Exosome Therapeutic Market Scope and Market Size

Global Exosome Therapeutic Market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Based on therapy, the market is segmented into immunotherapy, gene therapy and chemotherapy. Chemotherapy is dominating in the market because chemotherapy is basically used in treatment of cancer which is major public health issues. The multidrug resistance (MDR) proteins and various tumors associated exosomes such as miRNA and IncRNA are include in in chemotherapy associated resistance.

Based on transporting capacity, the market is segmented into bio macromolecules and small molecules. Bio macromolecules are dominating in the market because bio macromolecules transmit particular biomolecular information and are basically investigated for their delicate properties such as biomarker source and delivery system

Based on application, the market is segmented into oncology, neurology, metabolic disorders, cardiac disorders, blood disorders, inflammatory disorders, gynecology disorders, organ transplantation and others. Oncology segment is dominating in the market due to rising incidence of various cancers such as lung cancer, breast cancer, leukemia, skin cancer, lymphoma. As per the National Cancer Institute, in 2018 around 1,735,350 new cases of cancer was diagnosed in the U.S. As per the American Cancer Society Inc in 2019 approximately 268,600 new cases of breast cancer diagnosed in the U.S.To be continued..Detailed Segmentation ofExosome Therapeutic Market

The Countries Covered In The Exosome Therapeutic Market Report Are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific in the Asia-Pacific, South Africa, Rest of Middle East and Africa as a part of Middle East and Africa, Brazil and Rest of South America as part of South America.

Along with the elaborated information about the key contenders, the globalExosome Therapeutic Marketreport efficiently provides information by segmenting the market on the basis of the type services and products offerings, form of the product, applications of the final products, technology on which the product is based, and others. The report is also bifurcated the market on the basis of regions to analyze the growth pattern of the market in different geographical areas.

The Exosome Therapeutic Market report includes the leading advancements and technological up-gradation that engages the user to inhabit with fine business selections, define their future-based priority growth plans, and to implement the necessary actions. The global Exosome Therapeutic Market report also offers a detailed summary of key players and their manufacturing procedure with statistical data and profound analysis of the products, contribution, and revenue.

Global Exosome Therapeutic Market Report includes Detailed TOC points:

1 Introduction

2Market Segmentation

3 Market Overview

3.3 Opportunities

4 Executive Summaries

5 Premium Insights

6 Regulatory Procedure

7 Global Exosome Therapeutic Market, By Type

8 Global Exosome Therapeutic Market, by disease type

9 Global Exosome Therapeutic Market, By Deployment

10 Global Exosome Therapeutic Market, By End User

11 Global Exosome Therapeutic Market, By Distribution Channel

12 Global Exosome Therapeutic Market, By Geography

13 Global Exosome Therapeutic Market, Company Landscape

14 Company Profile

Continued!!!

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Visit link:
Exosome Therapeutic Market Size, Share, Trends, Global Research, Technology Implementation and Geographical Overview Till 2027 - Cole of Duty

Cardiac Stem Cells Comments Off on Exosome Therapeutic Market Size, Share, Trends, Global Research, Technology Implementation and Geographical Overview Till 2027 – Cole of Duty | May 24th, 2020

New research has identified two actives that can prevent stem cell decline as we age and increase collagen 17 levels in cells. It was published in Nature last year and has just been covered in Scientific American. The study was described as elegant by a prominent dermatologist, not involved in the project. As I am always on the look out for next big thing in antiaging skincare, I pounced.

Ill cut straight to the car chase. The two actives are Y27632 and apocynin and I was curious to see if they could be tracked down outside of a lab and, perhaps, in our potions and lotions. The first is a chemical that I havent been able to track down. Happily, I had better luck with apocynin.

Apocynin has been identified in a specific strain of cannabis, but also in cloudberry. And rubus chamaemorus (AKA cloudberry) seed oil is in a facial oil by Keracell. Ill post a link at the end of this article.

So, how do Y27632 and apocynin work? Emi Nishimura, a professor of stem cell biology at Tokyo Medical and Dental University in Japan, revealed that aging and UV exposure deplete stem cells of a crucial collagen protein. Heres what happens.

As part of normal skin health, the top layer of the epidermis is constantly being sloughed off and replaced from a self-replenishing pool of stem cells in the basal layer. These stem cells have roots that anchor them to a thin piece of tissue called the basement membrane that connects the epidermis and the dermis. Only when tethered can they replicate and mature into another type of cell.

This is where collagen 17 comes in. This collagen protein does the tethering (see the "adhesive molecule" in the illustration above), rooting the stem cell to the basement membrane. As stem cells become damaged, they lose precious amounts of collagen 17. The more protein they lose, the weaker their bond to the basement membrane, until eventually they are forced out by neighboring healthy cells.

Thats why this study is potentially a breakthrough. It has identified the process, the key protein that needs to be replenished and the chemicals that might just be able to do that.

You can find rubus chamaemorus (AKA cloudberry) seed oil and a potential source of apocynin in KERACELL Liquid Gold Enriching Elixir ($160 in the shop).

Become a member to read this article in full

Your membership includes:

Read the original here:
New research could be a breakthough in collagen and stem cell research - Truth In Aging

Skin Stem Cells Comments Off on New research could be a breakthough in collagen and stem cell research – Truth In Aging | May 23rd, 2020

Courtesy of Alexander (Sasha) Poltorak, Tufts University

The killer is not the virus but the immune response.

The current pandemic is unique not just because it is caused by a new virus that puts everyone at risk, but also because the range of innate immune responses is diverse and unpredictable. In some it is strong enough to kill. In others it is relatively mild.

My research relates to innate immunity. Innate immunity is a persons inborn defense against pathogens that instruct the bodys adaptive immune system to produce antibodies against viruses. Those antibody responses can be later used for developing vaccination approaches. Working in the lab of Nobel laureate Bruce Beutler, I co-authored the paper that explained how the cells that make up the bodys innate immune system recognize pathogens, and how overreacting to them in general could be detrimental to the host. This is especially true in the COVID-19 patients who are overreacting to the virus.

I study inflammatory response and cell death, which are two principal components of the innate response. White blood cells called macrophages use a set of sensors to recognize the pathogen and produce proteins called cytokines, which trigger inflammation and recruit other cells of the innate immune system for help. In addition, macrophages instruct the adaptive immune system to learn about the pathogen and ultimately produce antibodies.

To survive within the host, successful pathogens silence the inflammatory response. They do this by blocking the ability of macrophages to release cytokines and alert the rest of the immune system. To counteract the viruss silencing, infected cells commit suicide, or cell death. Although detrimental at the cellular level, cell death is beneficial at the level of the organism because it stops proliferation of the pathogen.

For example, the pathogen that caused the bubonic plague, which killed half of the human population in Europe between 1347 and 1351, was able to disable, or silence, peoples white blood cells and proliferate in them, ultimately causing the death of the individual. However, in rodents the infection played out differently. Just the infected macrophages of rodents died, thus limiting proliferation of the pathogen in the rodents bodies which enabled them to survive.

The silent response to plague is strikingly different from the violent response to SARS-CoV-2, the virus that causes COVID-19. This suggests that keeping the right balance of innate response is crucial for the survival of COVID-19 patients.

Heres how an overreaction from the immune system can endanger a person fighting off an infection.

Some of the proteins that trigger inflammation, named chemokines, alert other immune cells like neutrophils, which are professional microbe eaters to convene at the site of infections where they can arrive first and digest the pathogen.

Others cytokines such as interleukin 1b, interleukin 6 and tumor necrosis factor guide neutrophils from the blood vessels to the infected tissue. These cytokines can increase heartbeat, elevate body temperature, trigger blood clots that trap the pathogen and stimulate the neurons in the brain to modulate body temperature, fever, weight loss and other physiological responses that have evolved to kill the virus.

When the production of these same cytokines is uncontrolled, immunologists describe the situation as a cytokine storm. During a cytokine storm, the blood vessels widen further (vasolidation), leading to low blood pressure and widespread blood vessel injury. The storm triggers a flood of white blood cells to enter the lungs, which in turn summon more immune cells that target and kill virus-infected cells. The result of this battle is a stew of fluid and dead cells, and subsequent organ failure.

The cytokine storm is a centerpiece of the COVID-19 pathology with devastating consequences for the host.

When the cells fail to terminate the inflammatory response, production of the cytokines make macrophages hyperactive. The hyperactivated macrophages destroy the stem cells in the bone marrow, which leads to anemia. Heightened interleukin 1b results in fever and organ failure. The excessive tumor necrosis factor causes massive death of the cells lining the blood vessels, which become clotted. At some point, the storm becomes unstoppable and irreversible.

One strategy behind the treatments for COVID is, in part, based in part on breaking the vicious cycle of the cytokine storm. This can be done by using antibodies to block the primary mediators of the storm, like IL6, or its receptor, which is present on all cells of the body.

Inhibition of tumor necrosis factor can be achieved with FDA-approved antibody drugs like Remicade or Humira or with a soluble receptor such as Enbrel (originally developed by Bruce Beutler) which binds to tumor necrosis factor and prevents it from triggering inflammation. The global market for tumor necrosis factor inhibitors is US$22 billion.

Drugs that block various cytokines are now in clinical trials to test whether they are effective for stopping the deadly spiral in COVID-19.

[Get facts about coronavirus and the latest research. Sign up for The Conversations newsletter.]

Alexander (Sasha) Poltorak, Professor of Immunology, Tufts University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Read more:
Blocking the deadly cytokine storm is a vital weapon for treating COVID-19 - TheStreet

Bone Marrow Stem Cells Comments Off on Blocking the deadly cytokine storm is a vital weapon for treating COVID-19 – TheStreet | May 23rd, 2020

COVID-19 is not an equal-opportunity illness. Older people and patients with chronic conditions are, on average, far more vulnerable to suffering serious illness and death from the disease than younger people without ongoing health problems. Although the data are not as clear, cancer patients are also among those vulnerable to the SARS-CoV-2 virus that causes COVID-19 and more likely to suffer its serious consequences.

Oncologists around the country, supported and informed by guidance from healthcare leaders and professional associations, are reviewing the available research and carefully weighing treatment decisions. Many patients, with their physicians, are wrestling with question of whether the risks associated with putting off their cancer treatment are greater than the risk of COVID-19.

Randall Oyer, M.D., a medical oncologist at Lancaster General Health, a health system in Lancaster, Pennsylvania, says that in addition to understanding that cancer patients are a vulnerable group, healthcare leaders need to recognize that cancer patients are at heightened risk of contracting COVID-19 in the hospital.

Oyer says research from early COVID-19 hot spots such as China, Italy and the Seattle area suggests that patients with lung, liver and some types of gastrointestinal tumors, as well as hematologic malignancies, are at greater risk of suffering COVID-19 than patients with other kinds of cancer. Sparse as these data may be, they should still guide decision-making by oncologists and healthcare leaders, Oyer says. Many professional associations are providing guidance to oncologists during the outbreak, including the Association of Community Cancer Centers (Oyer is the president), the American Society of Clinical Oncology, the American Society of Hematology, the American Society for Radiation Oncology and the American College of Surgeons.

Agility and collaboration

Patients with cancers of the lung, the liver and possibly the gastrointestinal system are at increased risk of COVID-19 because the SARS-CoV-2 virus attaches to the angiotensin-converting enzyme 2 (ACE2) that is highly expressed in these organs and system, explains Oyer. ACE2 paves the way to cancer cells in these areas and acts as a welcome mat for SARS-CoV-2, he says.

Its a different story with hematologic cancers, which include the leukemias, the lymphomas and multiple myeloma. The cancers themselves reduce immunity and make people vulnerable to infection because they interfere with the production of healthy levels of lymphocytes. In addition, the treatment of hematologic cancers targets the immune system and the bone marrow to get rid of the malignant cells, but it also affects noncancerous cells, further suppressing the patients immunologic defenses. Oyer describes the process as one in which the bouncers (been) removed from the door and cant defend against the virus.

Masumi Ueda, M.D., M.A., assistant medical director for inpatient blood and bone marrow transplant at the Seattle Cancer Care Alliance, a hospital in its namesake city, says patients with compromised immune systems should adhere to the core recommendations for preventing COVID-19: Wash your hands, and maintain social distancing. Aside from that, theres not much more than we can do in the absence of a vaccine, she says.

Ueda was the lead author of an article in the April 2020 issue of the Journal of the National Comprehensive Cancer Network describing the changes that the Seattle cancer hospital made in response to the COVID-19 outbreak. The title is telling: Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal. Ueda and her colleagues mingled advice with brief accounts of the steps they took to respond to COVID-19:

Follow this link:
Cancer Care in the Time of COVID-19 and After - Managed Healthcare Executive

Bone Marrow Stem Cells Comments Off on Cancer Care in the Time of COVID-19 and After – Managed Healthcare Executive | May 23rd, 2020

THE world's top sports stars are preferring to use stem cell treatment, instead of undergoing major surgery that could leave them out for months.

Cristiano Ronaldo, Rafael Nadal, and most recently Mike Tyson have all tried the therapy, which can cost anywhere from 4,000 to 15,000, when they've suffered injury.

Ailments that can be treated, include tendon inflammation, muscle strain, arthritis, degenerative disc disease, and even bone fractures.

And sportsman who have undergone stem cell therapy are benefitting from improved results, as well as a faster recovery time.

Collected from the blood from a newborn babys umbilical cord, the bone marrow or from body fat, stem cells are injected into an athletes' affected area.

They get to work by replenishing damaged cells from an injury or through wear and tear.

Stem cells also help reduce pain and inflammation, increase blood flow, and promote soft-tissue growth.

It helps the body to heal naturally, and means sports stars can potentially avoid going under the surgeon's knife.

When you're a top sports star, if you get injured the first thing you want to do is get back into the thick of action as quick as possible.

Unfortunately, many injuries can take a long time to heal, and will never allow the sportsman in question to return to the same level he/she was at before the injury.

That's where stem cell treatment is a game-changer.

Forget surgery, steroid injections, and lengthy physiotherapy, which don't always repair the issue at hand.

Stem cell treatments offer an alternative, albeit at a price, to have a non-surgical therapy that's non-evasive and, more importantly, heals the problem fast cutting out the need of rehabilitation.

Better still, some patients have reported that the therapy has not only reversed existing damage, but has strengthened cells against further damage.

Juventus star Ronaldo and Spanish tennis hero Nadal are all fans of stem cell treatment.

Back in 2016, when the Portuguese forward was playing for Real Madrid, he suffered a hamstring tear that threatened to keep him out of action of an important Champions League game against Manchester City.

Although he missed the first leg, he was back for the second - less than three weeks after suffering the problem.

That same year, Ronaldo tore a collateral ligament in his knee during Portugals Euro 2016 final against France.

Again, he turned to stem cell treatment and was back in training with Los Blancos just a month after his knee complaint.

Nadal's chronic knee problems forced him to take seven months off from tennis in 2013.

But stem cell treatment allowed the cartilage to repair. In the seven years since he's won six Grand Slams, there's been no setbacks from his troublesome knee and he appears as mobile as ever.

The Spaniard also cured a long-standing back problem with the therapy.

The former heavyweight champion, who is considering making a comeback, is the latest name to have tried stem cell treatment.

EUR JOKINGCity, Chelsea & Man U's dreams in jeopardy as govt impose quarantine on arrivals

'ALWAYS SMILING'Ex-PSG ace Diakiese dies aged 24 as tributes paid for 'endearing boy'

Pictured

MIC DROPPEDLegendary WWE announcer Lilian Garcia shows off stunning beach body at 53

Pictured

ROSE TO FAMEWorld Series flasher Julia Rose posts outrageous snaps on Instagram

TIGER KINGWatch Mike Tyson spar and wrestle his 39st TIGER in shocking scenes

NET LOSSESTen stars who blew their football fortunes after reports Gyan has only 600

Pictured

A NEW PAIGEPaige VanZant's return set for July 11 on Fight Island vs Amanda Ribas

KEEP BEING YOURSELFMike Tyson tells Tyson Fury to 'stay the f*** away from normal'

It is not known what Tyson, 53, was suffering from - but he was happy to reveal all in an Instagram chat with basketball legend Shaquille O'Neal.

Iron Mike said: "You know what I had done? I had stem-cell research therapy.

"I feel like a different person but I can't comprehend why I feel this way. It's really wild what scientists can do."

Excerpt from:
Tyson, Ronaldo, and more sports stars who use stem cell treatment costing up to 15,000 to speed up healing - The Sun

Bone Marrow Stem Cells Comments Off on Tyson, Ronaldo, and more sports stars who use stem cell treatment costing up to 15,000 to speed up healing – The Sun | May 22nd, 2020

Before he knew Anuroop, Vihaan (right) addressed him as the Superhero.

Vihaan is a bright and active 4-year-old boy. He is a thalassemia survivor. And just over a year ago, he desperately needed a bone marrow transplant.

Anuroop, is a young man from Kerala. He doesn't know Vihaan's family. He just felt that donating bone marrow for someone in need was the right thing to do after he got a call from Datri, a non-profit agency coordinating such donations.

Anuroop told NDTV, "Actually, it was a matter of choice. I got a call from Datri about one year ago and they discussed with me this matter. They said, 'A 4 year old child, he is suffering from Thalassemia. Maybe only you can save him.' But at that point, I was not sure that I would do it. But later, with the support of my family and people from Datri, I decided to do it."

Anuroop and Vihaan came face to face - on camera - for the first time ever on NDTV. Anuroop was clearly emotional as he saw images of an active Vihaan, flanked by his parents, grinning and waving at the screen. Bhavana, Vihaan's mother was emotional too as she set eyes for the first time on Anuroop, who has given the family life and hope.

She told NDTV, "He is the answer to all our prayers. When Vihaan was diagnosed when he was 6 months old, we didn't know how Vihaan is going to be. We didn't know what to do. And then we went to Dr Sunil Bhatt and we registered with Datri. They told us that the procedure of finding a match is very difficult. And then we found a donor so we just couldn't believe that we were blessed to find a donor. Those were anxious days. But yeah, glad now."

Asked how her son was doing, Bhavana said, "Young Vihaan is doing great, thanks to Dr Sunil, thanks to Anuroop and thanks to God's grace. Vihaan is doing well."

Looking at the screen in front of her which showed, Anuroop, Dr Bhatta and Gayathri Shenoy of Datri, she told her son '"Just say hi, Vihaan!" He did, with a cheery wave.

Anuroop was moved by the response. He said, "I'm super excited - I waited for too long. I waited for one year. From that day of donation, the whole family, he was always in my prayers. I'm super excited now. That's all."

Finding a matching donor in a case like this is a very difficult task. Vihaan's doctor, Dr Sunil Bhatt, is HoD, Paediatric Haematology, Oncology, Bone Marrow Transplantation at the Mazumdar Shaw Cancer Centre in Bengaluru. And this professional medical man admitted to the deep emotions he feels at such times when a donor meets a recipient. "It gives me goosebumps," he told NDTV.

"You do so many times, again and again, but every time when an unrelated donor meets a patient - it is always an emotional moment for all of us," he said.

"Vihaan was diagnosed with a disease called Thalassemia at six months of age. What happens in this disease is that they don't make their own blood. So they have to be given blood transfusions from outside every few weeks to sustain life and that is life-long. But what blood does is it brings its own complications along with it and many of those and unfortunately most of these children do not live more than second or third decade of life. So the only cure for this is bone marrow transplantation and as we all know for Bone Marrow Transplantation we need someone to donate for them. There has to be a healthy donor who can donate," he said.

To find a matching donor is far from easy. Dr Bhatt said, "Sometimes you'll find that in the families - the chances of that being 25-30 per cent. But 70 per cent of the patients who require transplants will not have anyone in their families to donate for them. So here comes the role of unrelated donor transplantations that means someone else in the same country, in the world who matches the patient. And the chances of that being one in 20,000 to one in a million. So it depends on what ethnic background you're from - South Indian is going to match South Indian, North Indian going to match North Indian - chances will be higher in your own ethnic community. And hence the registries play a huge role because they enrol these unrelated healthy donors, put them on their database and when patients like Vihaan require such transplantation we approach these registries and ask them if there is any donor in the registry who is matching our patient. If there is one, that person is requested to donate and they donate stem cells to save someone's life."

Datri helped coordinate this life saving procedure with its all-important database. Gayathri Shenoy, Head-Patient Relations of Datri told NDTV, "I represent Datri which is India's largest blood stem cell registry. We are 10 years old and we have about 4.4 lakh registered donors and 712 donations of that. But as you can imagine that is a very small number compared to the population of our country because there are so many patients who have blood cancer who are waiting for their Anuroop to show up."

Asked if it had been physically difficult to donate bone marrow, Anuroop said, "Physically not that hard - like I need some rest but it is not that hard. Anyone can do it anytime if they find a match. I didn't find it very difficult and all. I heard some cases like people will be hesitant to do something like this - but I didn't find anything that should people hesitate. It is an easy process and you would be given a general anaesthesia. You won't be knowing anything."

Bhavana said, We just wanted to say that everyday in our prayers all of these people have been there. We didn't know the donor - so he was just addressed as the Superhero Donor, because it was very difficult to make Vihaan understand. Dr. Sunil, Datri - I don't know what we would have done if it was not for Datri. So just feeling blessed.

Here is the original post:
When A Bone Marrow Donor Met His 4-Year-Old Recipient For The First Time - NDTV

Bone Marrow Stem Cells Comments Off on When A Bone Marrow Donor Met His 4-Year-Old Recipient For The First Time – NDTV | May 22nd, 2020

Leukaemia is the cancer of blood cells. Blood cells originate from HSCs, hematopoietic stem cells, in the bone marrow. Thereafter they undergo maturation process called hematopoiesis. Multipotent hematopoietic stem cells often undergo a process of differentiation while in maturation stage to give rise to progenitor cells of myeloid and lymphoid origin. These Myeloid cells include neutrophils, basophils, monocytes, macrophages, erythrocytes, dendritic cells, eosinophils, and megakaryocytes or platelets. While, Lymphoid cells include B cells, T cells and natural killer cells.

Recently in 2016, Global Leukaemia Therapeutics Market was valued at nearly USD 9.44 billion and is expected to grow at a CAGR of 4.1% between 2017 and 2022, accounting to market worth USD 11.97 billion by end of 2022.

The Final Report will cover the impact analysis of COVID-19 on this industry.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10064998

Normally, the blood forming cells in the bone marrow produce leukocytes, that protects against viruses and bacteria. If these leukocytes get damaged and if they are left untreated they get accumulated in the body and invade in other parts like liver, spleen and central nervous system, hence damaging the entire body. The main reasons causing leukaemia are ionizing radiation, smoking, prior chemotherapy and Down syndrome.

Market Dynamics

Recently in 2016, Global Leukaemia Therapeutics Market was valued at nearly USD 9.44 billion and is expected to grow at a CAGR of 4.1% between 2017 and 2022, accounting to market worth USD 11.97 billion by end of 2022.

Global Leukaemia Therapeutics market is majorly driven by the growing number of incidences of target disease across the globe. Also, development of novel agents, advancements in technology and combination therapy with reduced side effects and better survival conditions are some other key factors that drives the Leukaemia Therapeutics Market.

However, the high cost of combination therapies and clinical trials coupled with post-treatment complications, adverse events and side effects are the major constraints that limit the growth of the market.Nevertheless, initiatives like increasing focus on healthcare and personalized medicine along with huge govt. investment & R&D in anti-leukaemia therapeutics research are sure short to boost the market growth in the near future.

Market SegmentationGlobal Leukaemia Therapeutics Market can be segmented as follows :Segmentation by TypeChronic leukaemiaChronic myeloid leukaemiaChronic lymphatic leukaemiaAcute leukaemiaAcute myeloid leukaemiaAcute lymphatic leukaemia

Request For Full Report:https://www.kennethresearch.com/sample-request-10064998

Segmentation by TherapyBiological TherapyRadiation therapyChemotherapyTargeted therapy

Regional/Geographic AnalysisEurope, North America, Latin America, Asia-Pacific, Middle East & Africa are key market segments of global Leukaemia Therapeutics. North America is the leading region and is anticipated to remain one in the near future, over the forecast period. Demand for leukaemia therapeutics was highest in North America especially in the U.S attributing to increasing geriatric population and increased number of cases. While, Asia Pacific region along with Middle East, Africa and Latin America is expected to grow at moderate pace.

Key Players

The key players in global leukaemia therapeutics market includeF. Hoffmann-La Roche Ltd., Bristol-Myers Squibb, Amgen, Pfizer, Teva Pharmaceuticals, Novartis International AG., GlaxoSmithKline plc., Genzyme Corporation, AbbVie Inc. and others.

About UsKenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation.

Contact UsKenneth ResearchEmail:[emailprotected]Phone:+1 313 462 0609

Originally posted here:
Leukaemia Therapeutics Market is expected to grow at a CAGR of 4.1% between 2017 and 2022 - WaterCloud News

Bone Marrow Stem Cells Comments Off on Leukaemia Therapeutics Market is expected to grow at a CAGR of 4.1% between 2017 and 2022 – WaterCloud News | May 22nd, 2020

Indias slum population is ill-prepared to face the novel coronavirus disease (COVID-19) pandemic, with livelihoods threatened as a consequence of the lockdown

The novel coronavirus disease (COVID-19) pandemic infected over four million people worldwide as of May 7, 2020 and killed over 200,000 people. After receiving its first cases on January 28, India witnessed a spike in late March, that led to a nationwide lockdown on March 24 in order to stem the infection.

The number of cases, however, only increased in the past couple of months. As of May 10, 63,975 cases were reported, mostly in densely populated and highly urbanised areas, resulting in almost 2,109 deaths.

One of the measures adopted by the Union and state governments following World Health Organization guidelines was to tell people to stay home and follow the practice of social distancing where emphasis is laid on the maintenance of distance of at least six feet between individuals.

Access to safe drinking water, proper sanitation and health conditions to protect from the infection is necessary to stop human-to-human transmission along with ensuring good consistency in hand washing and waste management practices.

A question, however, emerges over the efficacy of such measures, given that India has the second-most dense population in the world, with a less than adequate healthcare system and a high migration rate, compounded by the fact that 21.9 per cent of the countrys total population lives below the poverty line, according to 2018 data from the National Sample Survey Office.

Is social distancing a viable strategy for this largely informal society? Can a largely poor population, consisting primarily of marginalised communities and migrant daily wage workers adopt such strict guidelines?

We focus on this question by analysing the socio-economic conditions of people living in informal urban settlements and slums within the country.

What is clear is that the slum population is ill-prepared to fight the pandemic, with livelihoods threatened as a consequence of the lockdown. It also sounds impractical to assume slum households have hygienic access to water, toilets, sewers and drainage in informal settlements.

In overcrowded slums, measures like physical distancing and self-quarantine remain far from implementation.

Dharavi Asias biggest slum located in Mumbai with an approximate one million population shows this reality. As on April 29, Dharavi reported a total of 590 cases, with 20 deaths. These deaths include youth and children, according to a media report.

Researchers from the Centre for Sustainability estimate the reproductive ratio (R naught) for the SARS-CoV-2 virus that causes COVID-19 on a global scale. They suggest this number in India's slums to be 20 per cent on an average, higher because of dense living conditions, according to a report in news daily Hindustan Times. This vulnerability is borne out in statistics as well.

We analysed data from the fourth round of the National Family Health Survey (NFHS-4) and the 2011 census, focusing on more urbanised states like Maharashtra, Madhya Pradesh, Uttar Pradesh, Delhi, Tamil Nadu and Telangana.

Within these states, we further classified urban households residing in slums in Mumbai, suburban Mumbai, Nagpur, Indore, Meerut, Hyderabad, Chennai and Delhi.

Distribution of SARS-CoV-2

To begin with, we described the basic characteristics of confirmed cases of the virus in Indian states, with basic calculations from COVID-19 India. We analysed details such as growth rate, fatality rate, recovery rate, test per million and share of active cases.

Basic method to understand the novel coronavirus pandemic select states in India

Source: NFHS-4, Census-2011,COVID19

Based on the reported rise in the pace of infection in various states, we attempted its association with share of migrants and slum population. The statistics indicate a clear pattern of intensity among major cities.

The share in total active COVID-19 cases is higher in Maharashtra (36.4 per cent per million), followed by Gujarat (12.5 per cent), Tamil Nadu (12 per cent) and Delhi (10.9 per cent).

With respect to fatality rates, West Bengal, Gujarat and Madhya Pradesh lead the table. Recovery rate too, follows the same trend with the notable exceptions of Kerala and Telangana.

When one reads the pace of increase in infection, it is evident that the most urbanised and in-migration states like Maharashtra, Delhi, Gujarat and Telangana according to the 2011 census show higher incidences of infection.

At the same time, there is a reasonable rise in COVID-19 cases in Bihar, Jharkhand, West Bengal and Uttar Pradesh because of reverse migration following the lockdown.

On the other hand, its association with the degree of urbanisation may very well be due to under-served and under-privileged residents with limitation of housing and basic amenities that inhibits adhering to the required prevention protocol. The most vulnerable therefore become the slum residents with poor sanitation practices.

Percentage of the novel coronavirus cases and risk in select urban districts

Source: NFHS-4, Census-2011, COVID-19.org

Approximately 65 million people, or 22 per cent, of Indias total population lives in urban slums, according to a report. Most of the temporary and semi-temporary migrants, however, live in slums across major cities.

A few districts of Maharashtra, including Mumbai, suburban Mumbai and Nagpur are home to 1.39 million temporary migrants and 5.74 million semi-permanent migrants.

These migrant labourers form the backbone of Indias economy, work on lower daily wages and do not have the privilege of working from home with stable wages.

They either risk infection to work in the current lockdown or face unemployment and starvation. It is these workers who are prone to a higher risk of comorbidity and consequently at a greater risk to get infected with the virus.

Risks with migrants, slum households

When we look at migrants, they mainly live in metropolitan hubs, including Mumbai, Delhi and Chennai and are vulnerable due to the informal nature of their livelihoods in these slums.

While associating the share of migration and the quantum of infection, we find a positive correlation indicating the migration related vulnerability of this infection. This association is further strengthened when one considers the share of the most vulnerable population living in the urban slums of Mumbai, Central Delhi, Chennai and Hyderabad with a positive correlation.

SARS-CoV-2infections correlation with migrants within slum households

Assessing social distancing, sanitation

Slum lanes are so narrow that when we cross each other, we cannot cross without our shoulders rubbing against the other person, said a slum dweller, quoted by international news outlet The Guardian. This is, unfortunately, the case in most slum pockets in India.

The World Economic Forum, for example, said Dharavi has a high population density of over 270,000 people living per square kilometre.

This undoubtedly makes social distancing norms impractical. Most of the migrant families or migrant workers who live in single rooms depend oncommunity toilets and water taps.

Findings from NFHS-4 show that among slum households, 56.94 per cent use unimproved toilets, 63.76 per cent live in one room tenements and 76.25 per cent have limited access to water for hand wash.

Unsurprisingly, the evidence shows a positive correlation among virus infections and residences with unimproved toilet facilities, one room households and unavailability of water.

For almost all slum households, using hand sanitiser is very expensive and moreover, access to water for hand-washing is inadequate to begin with. Maintaining social distancing is also not possible given the high density of the population within these slums.

The current crisis should send alarm bells ringing for governments and urban planners in the country over the sustainability of our cities for its citizens. Ensuring good and consistently applied water sanitation and hygiene and waste management practices in communities is a pre-requisite for containing the spread of the epidemic.

Given the evidence on living reality of slums residents and urban migrants in Indian cities, norms like social distancing and hygiene practices seem far from reality.

SARS-CoV-2correlation with hygiene and sanitation conditions in slum households

Policy implications

The analysis highlights the inadequacies of human living and its vulnerability in the face of a pandemic. Overcrowded slums in major cities house an important but extremely vulnerable section of our society.

This population was severely affected due to both the typical infectiveness of the virus as well as the lockdown, leading to substantial losses in lives and livelihoods of these people.

A Stranded Workers Action Network survey recently conducted across various states showed out of 11,159 migrant workers, 96 per cent did not get ration and 90 per cent of them did not get wages.

In case of such an outbreak and the associated measures for its containment, basic deficiencies of the urban poor are overlooked, not just in terms of their compromised living, but also limited access to medical care. It is evident that measures adopted originate from a middle-class mindset that assumes a lot more and is remote from prevailing realities.

This pandemic is a reminder for the need of a slum emergency planning map for every urban settlement and developed solid waste management strategy.

Most importantly, urban planners need to urgently rethink about the sustainability of mega cities in the wake of the outbreak. We have seen vulnerable populations disproportionately affected all the worlds major cities from Wuhan in China, to New York in the United States and Mumbai and Delhi in India.

While the more privileged sections of society have the luxury of sequestering themselves and maintain social-distancing, large swathes of people who do not have the luxury to do so often suffer.

This episode should is an eye-opener to reveal that if we are to recover from crises in the future, we need to strengthen and equip the basic health and public health infrastructure of the urban cities to cater to all its residents to guarantee sustainable urban living.

We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.

Read the rest here:
COVID-19: How do India's urban informal settlements fight the pandemic - Down To Earth Magazine

Cardiac Stem Cells Comments Off on COVID-19: How do India’s urban informal settlements fight the pandemic – Down To Earth Magazine | May 22nd, 2020

Are you hallucinating or are you seeing the same face everywhere? You know the one. Highly sculpted. Quasi-"exotic." Suggestively cyborgian with equidistant almond eyes, '90s-supermodel high cheekbones and a poufy cupid pout. Dubbed "Instagram Face" in a New Yorker article by writer Jia Tolentino, it's an exactingly symmetrical look facilitated over the last decade by high-tech advancements in digital facial-tuning filters and injectable facial fillers, aka tweakments, aka the minimally invasive cosmetic procedures that have made Botox and Juvderm household names. Filters and fillers.

Though this chiseled face devoid of smiles, frowns, furrowed brows of worry or concentration and wrinkles is primarily found on women, it was, in many ways, a face forged by men. As of 2018, 85% percent of board-certified plastic surgeons in the US were male, while 92% of their patients were female. Meanwhile, Facebook, which owns Instagram, home to some of the most popular filters behind these trends, has a tech workforce that was, as of 2019, 77% male.

Historically, this "Oz behind the curtain" dynamic when it comes to "ideal femininity" is not new. From 1950s advertising executives brainstorming buxom, button-nosed visions of domesticity to 1980s filmmakers placing a prepubescent Brooke Shields in The Blue Lagoon's thinly veiled mainstream erotica, men in positions of power have consistently manufactured the American beauty construct.

And, like any functioning ideology, that construct has mutated to mirror its moment. The face of the 2010s indeed, the supposedly ideal face at the core of the beauty paradigm for eons has often relied on an essential recipe that Dr. Andrew Jacono, a prominent New York plastic surgeon and author of 2019's bestseller The Park Avenue Face, likens to the perfectly balanced proportions reflected in the wings of a butterfly or the gothic cathedrals of France. But remember in the early '90s when we sea-changed seemingly overnight from the flawless buoyancy of Cindy Crawford to the fucked-up teeth and waifish "heroin chic" of Kate Moss? Apart from the golden ratio, there is another beauty truth we could probably all agree upon: The trend pendulum eventually swings. Does that mean that we're in for a face envisioned by women? And, if so, what would that face look like? Could we imagine it might appear not less but more emotive?

In sharp contrast to the tacit perfectionism of filter/ filler plasticity, Doniella Davy, the makeup artist for HBO's aesthetic bombshell Euphoria, said in an interview with Allure that she, herself, leaves the house every day in a different color of glitter or eyeliner because she's presenting herself to the world in a way that feels authentic. "I don't need anyone's approval," she put it. Similarly, rather than using makeup to convey a character's stereotypical core identity in keeping with traditional Hollywood sets, Davy applies a Technicolor palette to the show's stars as a way to signal their changing and changeable emotional states. It's a vibe makeup artists like Pat McGrath, who rhinestoned eyebrows and gilded undereyes for Marc Jacobs' Spring 2020 New York Fashion Week show not to mention drag queens and the LGBTQIA communities have been experimenting with since the dawn of time. Lady Gaga and Lizzo clearly got the memo. But the crayon box sensibility does seem to hold a new grip on our collective cultural imagination. According to Google Trends, the search term "glitter eye" spiked in September in the wake of NYFW Spring 2020, then again in February on the night of the Oscars, when Janelle Monae showed up in a hooded dress dripping with thousands of crystals part Little Red Riding Hood, part disco ball matched by glittery silver eyeliner and cherry red lips.

One potentially telling facet of these new trends' appeal is the fact that they leave much more room for experimentation and customization. Because if beauty is based not just on symmetry but also on value and rarity, and if a glut of influencers have all bought the same injectable features and nearly anyone can go out and mimic them by following one of thousands of rote YouTube tutorials with a highlighter stick and some concealer, does that face even look special anymore? What, then, will we all be fixating on in the decade ahead? Look a little closer at Euphoria. There is a common denominator: Across moods and characters, the skin beneath operates like a clean canvas. It looks raw, fresh, tween. And its desirability isn't limited to the show, to 20-somethings or to Hollywood. It's already attracted a cultish, worldwide following.

The Korean beauty world calls it "glass skin." The basic properties are pristine porelessness and crystalline clarity. We can supposedly achieve glass skin by slathering ourselves daily with several kinds of moisturizers, toners, hydrophilics and exfoliants following a bajillion-step K-beauty routine. Or, in certain states where it is legal, we could have semi-permanent BB Glow pigment microneedled into our skin. But one downside to tattooing fake skin into actual skin is that BB Glow needling is not FDA approved and runs the risk of severe allergic reaction, among other untested, uncharted waters. Artificial intelligence could help. As though to underscore our oncoming skin-tone mania, at CES, the tech expo in Las Vegas this January, the two main beauty attractions were Procter & Gamble's Opt wand and L'Oral's Perso, both AI gadgets that purport to scan and analyze skin in order to optimize the camouflaging of spots, sunspots and hyperpigmentation over time.

Plastic surgeons, whose procedures, injections and treatments have proffered permanent (or semi-permanent) versions of the contouring and highlighting that ruled the 2010s, are also thinking about how this pendulum shift could affect their practices. "When times are harder and people have to work harder, more chiseled, masculine features become more desirable. Because of this, in the last decade, you saw a lot of chiseled features come into play," Dr. Simon Ourian, a cosmetic dermatologist, tells me, in the glitzy waiting room of his Rodeo Drive enclave, Epione, an aesthetic surgery center in Beverly Hills. Referring to the economic challenges of the Great Recession and its recovery over the last decade, he goes on to say, "Women who were trying to show their strength and independence came to fruition by showing very strong features." But, he adds, for centuries, when the economy is strong, as it seems to be now, society has appreciated a softer, "more feminine look."

Ourian invented the Coolaser, a cosmetic dermatology office mainstay that evens skin tone. He is also the A-list's go-to expert in Hollywood, counting among his openly vocal celebrity clients Miley Cyrus, Iggy Azalea, Lady Gaga and the entire Jenner-Kardashian clan, including Kylie and Kim.

We talk about what, specifically, that new softer look might be led by, now that the chiseled cheekbones, chins and jawlines Ourian pioneered have become a worldwide phenomenon. Given his inside line, I'm hoping he'll share what the starlet subset is starting to request that they weren't requesting a year ago. He defers, not wanting to dictate trends from his "little office in Beverly Hills," but he admits he derives all of his trend intel from Facebook and Instagram, casually mentioning, on the subject of the platforms' instantaneity, the summer boob job. "Temporary breast augmentation started a few years ago because now we can inject fillers into the breasts and they go away after a few months," he explains. "So if you don't want to commit the rest of your life to being one or two sizes bigger, you can try it for a summer and fit better into your bathing suit." (And, judging by the rash of articles about the surge of temporary, non-invasive "Botox brow lifts" among the same cohort of stars and influencers who personify "Instagram Face," it's not just lips and breasts that are getting these temporary enhancements.)

And does this mean a person could theoretically "try on" Ourian's signature cheekbones too? Will party prep soon include the prosthetic cheekbones that paraded down Balenciaga's controversial Spring 2020 runway? According to Ourian, yes. "You can do the same thing with your face," he says. "You can get a filler in your face that lasts a month or two and if you don't like it, it goes away ... It's like trying something on in a dressing room. That appeals to the concept of the Instagram generation who want to change a filter and see how they look."

Whatever strange, weird extremes the fashion world might pursue, however, Ourian maintains that neither of those two adjectives should be confused with beauty. "One definition of beauty has been average," he notes. "You take a thousand people in a society and you superimpose that face. The average of those faces is what's considered to be beautiful by the people of that society, because they are not very strange." But one thing, he admits, has changed: "Now that instead of seeing a thousand people, our eyes are used to seeing millions of people because of the internet, our average has expanded."

In keeping with our ocular intake's exponential widening, Ourian concedes that the spectrum for what could be considered beautiful has expanded. Noses, he says, are no longer really a thing. "Ten years ago if you showed someone with a larger behind or a larger nose or a different skin color, few people would jump at it and say that's beautiful," he says, citing the model Winnie Harlow, who's rendered the skin condition vitiligo no less a beauty disqualifier than blue eyes or blond hair. But symmetry, he emphasizes sternly, will never go away. Rather than a cathedral, he points to the sleek sofa I'm sitting on and says pointedly, "Even furniture looks better when it's symmetrical."

After a decade of the Ourian-Kardashian beauty dynasty, however, LA's young, rising beauty vanguard seem to be ready for a look that's less kittenish, more renegade. When I meet up with 26-year-old photographer Kelia Anne MacCluskey, who's shot for PAPER, Playboy and The New York Times, and her boyfriend Lucky Pettersen, 27, a casting director who's cast campaigns for Gucci, Levi's and Calvin Klein, for drinks at a tapas spot in Highland Park, both suggest in their own way that they're constantly searching for models and talent with gap teeth or a unibrow, the sort of authentic, identifying mark that makes an instant, unforgettable impact. Pettersen, for example, philosophizes on Gen Z's desire for honesty as exemplified by 22-year-old model Salem Mitchell. After trolls compared her freckled skin to overripe fruit, Mitchell launched herself on Instagram by posting a photo in response, hashtag #bananaface.

Yet as empowering as a swing toward this aesthetic individualism might sound, it would be nave to assume that any new trend would outright eschew the inherent pressures of the beauty paradigm. New standards will be set, new expensive treatments spawned. At the moment, unibrows and sequin brows aside, all overarching signs point to a standard centered on pristine skin.

In Perfect Me, a book about the perils of our current global beauty ethic, British academic Heather Widdows attributes this growing preoccupation to a "forensic gaze" fueled by visual culture and the omnipresence of hi-def screens and cameras that require us to look smooth and luminous "not just when our picture is likely to be taken (on holidays or at weddings), but increasingly all the time ... given that we can imagine ourselves (or our failings) being photographed in almost any context." In an interview with PAPER, she cautions that the "forensic gaze of HD TV and selfie culture is something we need to take much more seriously as shaping who we think we are and putting pressure on us to perfect our faces in ways that really aren't possible for living, breathing, sweating, aging human beings." She also argues that the widening of the beauty spectrum under the auspices of the internet might actually be just the opposite: a contraction. Whereas, pre-internet, beauty norms were decided by the more localized scopes of one's cultural community into micro-ranges, these ranges are converging into a more singular worldwide beauty window with less room for divergence: "thin and slim, with breasts and butt curves, smooth, luminous, glowing skin, and large eyes and lips ... White women are just as unable to attain the beauty ideal without intervention as Asian and Black women are," she says.

But what if we could regrow our own genuine genetic skin the way it looked before sun damage, cigarettes, sleeplessness, acne and other little scars set in?

What if we rolled out of bed in the morning and didn't have to waste a single second thinking about makeup, let alone fueling the industrial beauty complex and its ecological fallout with our hard-earned third-wave feminist salaries because we'd woken up in our own living, breathing, sweating childhood skin? "That is truly the holy grail of cosmetic dermatology," according to Ourian. "What makes a kid's skin perfect aside from the fact that they haven't been exposed to the environment their skin repairs itself much faster," he explains. Up until now, there was no way to unlock the skin's reparative memory. Ourian gets enthused again. Declaratively, he pronounces: "Stem cells are going to be the biggest thing." And he's not talking about the Vampire Facial craze. He does not think having one's skin needle-scratched raw and bloody before pouring stem cell serum derived from placentas onto it is of any use. No, if you ask Ourian, the holy grail, the next Botox, is injectable skin.

In his office, he already performs a version of it with stem cells derived from the patient, but it's expensive and not as efficient or effective as Ourian believes it will soon become. "First I have to get rid of all the old junk, Coolaser to get rid of the sun damage," he explains. "To get this baby skin we have to retrain it to keep itself healthy, and that's where the stem cells come in ... but in the next five or ten years we will achieve a level of age reversal that will mimic the way your skin was in your 20s or pre-teens." He's hoping it becomes as mainstream as Botox: "For a few hundred dollars, you can get it done."

Then and now, there will always be the non-conformists who consciously push back against the ever-tightening beauty construct, whether it's dictated by Kim-face, Glass-face or any face in between. The artists, activists, intellectuals and outsiders: Alicia Keys, Salem Mitchell, Frances McDormand, Heather Widdows, maybe your daughter or son or nonbinary child, maybe mine. For her part, Widdows has this advice for anyone who wants to help broaden beauty norms: "Call out 'lookism.' We need to name it (as we once named sexism) and make body shaming not and never okay." In the meantime, Simon Ourian will be chasing his white whale. As we age, the extraorbital fat pads that cushion our eyeballs in our ocular sockets erode, and the eyes sink into the face. "We can put a fat pad in the back of the eyes surgically, but not in a quick procedure," he explains. "So that keeps me up at night. How do I put fat pads back behind the eyes without cutting faces?"

From Your Site Articles

Related Articles Around the Web

See more here:
What's the Next '"nstagram Face"? - Papermag

Skin Stem Cells Comments Off on What’s the Next ‘"nstagram Face"? – Papermag | May 21st, 2020